Cargando…

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

BACKGROUND: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies. METHODS: We detected ALK protein expression by immunohistochemistry and gene rearrang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amatu, Alessio, Somaschini, Alessio, Cerea, Giulio, Bosotti, Roberta, Valtorta, Emanuele, Buonandi, Pasquale, Marrapese, Giovanna, Veronese, Silvio, Luo, David, Hornby, Zachary, Multani, Pratik, Murphy, Danielle, Shoemaker, Robert, Lauricella, Calogero, Giannetta, Laura, Maiolani, Martina, Vanzulli, Angelo, Ardini, Elena, Galvani, Arturo, Isacchi, Antonella, Sartore-Bianchi, Andrea, Siena, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701996/ https://www.ncbi.nlm.nih.gov/pubmed/26633560 http://dx.doi.org/10.1038/bjc.2015.401

Ejemplares similares

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017)

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
por: Milione, Massimo, et al.
Publicado: (2017)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion
por: Liu, Stephen V., et al.
Publicado: (2017)

Mining potentially actionable kinase gene fusions in cancer cell lines with the KuNG FU database
por: Somaschini, Alessio, et al.
Publicado: (2020)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer
por: Na, Il-Kang, et al.
Publicado: (2015)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Chemical Proteomic Analysis Reveals the Drugability of the Kinome of Trypanosoma brucei
por: Urbaniak, Michael D., et al.
Publicado: (2012)

Reaching Un-Drugable Intracellular Targets with the Long Arm of Antibodies
por: Scheinberg, David A., et al.
Publicado: (2013)

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1
por: Bosotti, Roberta, et al.
Publicado: (2017)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Glutamine Synthetase Drugability beyond Its Active Site: Exploring Oligomerization Interfaces and Pockets
por: Moreira, Cátia, et al.
Publicado: (2016)

Comprehensive kinome NGS targeted expression profiling by KING-REX
por: Carapezza, Giovanni, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Assessment of the drugability of initial malaria infection through miniaturized sporozoite assays and high-throughput screening
por: Miglianico, Marie, et al.
Publicado: (2023)

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
por: Krebs, M.G., et al.
Publicado: (2021)

Prognostic Importance and Therapeutic Implications of PAK1, a Drugable Protein Kinase, in Gastroesophageal Junction Adenocarcinoma
por: Li, Zongtai, et al.
Publicado: (2013)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

ALK Inhibitors, a Pharmaceutical Perspective
por: Ardini, Elena, et al.
Publicado: (2012)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Entrectinib for non-small cell lung cancer and solid tumours
Publicado: (2020)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6s2g2q56lg5atdj3a9prefth4k